Understanding X-linked Moesin Associated Immunodeficiency
Official title: Etude Multicentrique Internationale rétrospective Des Patients Atteints de déficit Immunitaire associé à la moésine lié au Chromosome X (X Maid Pour X-linked Moesin Associated Immunodeficiency)
Run by Institut National de la Santé Et de la Recherche Médicale, France · NCT06278337 · Data updated 2026-11-12
This study looks at how to better treat boys with X-linked Moesin Associated Immunodeficiency by collecting health information to understand their infections and the effects of their genetic mutations.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 4 Years to 80 Years |
| Sex | Men only |
| Enrollment | 16 (estimated) |
| Sponsor | Institut National de la Santé Et de la Recherche Médicale, France Government |
| Locations | 10 sites (Bethesda, Maryland and 9 other locations) |
| Status | Recruiting |
| Started | August 12, 2021 |
| Main results expected | August 12, 2026 |
| Study ends | January 12, 2027 |
| Registry record updated | April 25, 2025 |
| Trial ID | NCT06278337 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are male patients with a mutation in the MOESIN gene.
✕Probably not a fit
Patients without a mutation in the MOESIN gene or those who do not consent to the collection of personal health data may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on X-linked Moesin Associated Immunodeficiency (XMAID), characterized by recurrent bacterial infections and specific genetic mutations in the moesin gene. The study aims to review the clinical presentation and management of affected male patients, gathering data from various countries to establish treatment guidelines. Participants will be male patients with identified mutations in the MOESIN gene, and the study will involve the collection of personal health data to better understand their conditions and treatment responses.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and management strategies for patients with XMAID, potentially reducing the frequency and severity of infections.
How similar studies have gone: While this study builds on previous findings regarding moesin deficiency, it aims to establish a more standardized approach to treatment, indicating a novel aspect in the management of this condition.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male patient with a mutation in the MOESIN gene (MSN) * No objection to the collection of personal health data Exclusion Criteria: \-
Where it's running
-
Hôpital Necker
Paris, Paris, France Recruiting -
CHU Rennes, CNRS UMR 629
Rennes, France Recruiting -
National Institutes of Health
Bethesda, Maryland, United States Not yet recruiting -
Perelman School of medecine
Philadelphia, Pennsylvania, United States Not yet recruiting -
Brown University
Providence, Rhode Island, United States Not yet recruiting -
Genomic Research Centre, School of Biomedical Sciences Institute of Health and Biomedical Innovation
Brisbane, Australia Not yet recruiting
Show 4 more locations
-
Hôpital Universitaire de la Reine Fabiola
Brussels, Belgium Not yet recruiting -
CHU St Etienne Hôpital Nord
Saint-Etienne, France Not yet recruiting -
Tokyo Medical and Dental University (TMDU)
Bunkyō City, Japan Not yet recruiting -
Departments of Internal Medicine and Immunology
Rotterdam, Netherlands Not yet recruiting
Study contacts
- Principal investigator: Isabelle ANDRE, doctor — Institut National de la Santé Et de la Recherche Médicale, France
- Study coordinator: Isabelle ANDRE, Doctor
- Email: isabelle.andre@inserm.fr
- Phone: 01 42 75 43 37
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI analysis of ECGs to detect structural heart disease
This project will test whether AI can read traditional and wearable ECGs to find undiagnosed valve disease, pulmonary hypertension, and heart failure in adults.
-
ETHY-001 safety and activity in Thyroid Eye Disease (TED)
This study tests ETHY-001 versus placebo to see if it is safe, tolerable, and shows activity in people with thyroid eye disease.
-
CR-402 treatment for refractory autoimmune disease
This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.
-
Music-4-MS: A 12-week music-based program to support thinking skills in people with MS
A 12-week music-based program is tested to see if it helps cognitive function and mood in people living with multiple sclerosis.
-
ATG-201 in adults with autoimmune diseases
This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.
-
AMX0035 in adults with Type 1 Diabetes
This study tests whether 24 weeks of the oral medication AMX0035 help improves metabolic health in adults with Type 1 Diabetes compared with a placebo.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.